Kenny Walter

There are several companies preparing new treatments for recurrent C difficile infections.

There are several potential treatments on the horizon for C difficile infections.

Patients treated with ustekinumab are not at an increased risk of malignancies.

Treating the disease could reduce the risk of patient distress.

There are several live microbiota therapeutics in development, including RBX2660.

The treatment has previously been approved by the FDA for the treatment of ulcerative colitis.

The age of screening for colon cancer has decreased in recent years.

Dr. Dubinsky said new IL-23 treatments could enable precision medicine in the future for IBD.

The treatment recently became the first ever FDA-approved medication for EoE.

Initial studies have shown a 73% efficacy for FMT in treating patients with HVGD.

The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.

Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.

Patients treated with TNF- antagonists had a higher deep remission rate compared to patients treated with ustekinumab.

Patients with IBD are often at an increased risk of developing NAFLD.

The data presented at DDW show similar safety and efficacy for the 2 treatments.

Recurrence commonly occurred during the first 2 weeks regardless of treatment.

Both post-transplant PPI and histamine-2 receptor antagonist use were independently associated with reduced risk of 1-year mortality.

The treatment did not improve sustained virologic response but did increase the rate of treatment-related adverse events.

There remains a need for longer-term observational studies comparing the 2 treatments.

Dr. Chopra said an FDA-approved treatment for NAFLD could come in the next 6 months.

Dr. Tara Vijayan talks about how primary care physicians can be best combat misinformation.

Alcohol use increased during the COVID-19 pandemic, leading to an increase in alcoholic hepatitis.

High-risk individuals should be targeted when drug scarcity comes into play.

NAFLD is currently the most prevalent liver disease in the US.

There remains a need to develop more antivirals that can be easily scaled up for COVID-19.

Significantly more patients treated with upadacitinib achieved clinical remission compared to patients treated with placebo.

Dr. Charles Vega suggestion doctors be less prescriptive in suggestion diets to patients.

Drugs like semaglutide are able to treat both diabetes and obesity.

Dr. Michael Ziffra talked during Pri-Med West 2022 about some of the challenges and gaps in research needed for better bipolar disorder care.

Jennifer Green discussed weight management and obesity during the annual Pri-Med West conference.